Tomer M Mark, M.D., MSc
After completing fellowship at New York Presbyterian Hospital - Weill Cornell Medical Center under the mentorship of Dr. Ruben Niesvizky, I have joined the Center for Lymphoma and Myeloma as a full-time clinician with a focus on clinical and translational research. I hope to provide excellent care to persons with multiple myeloma and other plasma cell disorders in the context of advancement of the clinical knowledge of these diseases. Our approach at the practice is to improve upon the standard of care and provide a broad range individualized treatment for each unique patient, be it from oral treatments, to chemotherapeutics, to stem cell transplant.
Our goal at the myeloma practice at Weill Cornell is to one day find a cure. We are working diligently and making progressive strides towards this end; currently, we are bringing the latest advancements to patients with plasma cell disorders into regular clinical practice.
Dr. Tomer Mark is an associate professor of clinical medicine at the Weill Cornell Medical College. He specializes in seeing patients with multiple myeloma and other plasma cell disorders, with a focus on stem cell transplantation and clinical trials.
Dr. Mark grew up in New York where he attended public school. He graduated from the Bronx High School of Science in 1994. Dr. Mark graduated from Yale University in 1998 and went to medical school at the State University of New York at Stony Brook, where he graduated with a medical degree with recognition in research. He did his Internal Medicine Residency training at Beth Israel Deaconess Medical Center, Boston, MA. and completed his Hematology and Medical Oncology Fellowship at New York Presbyterian Hospital: New York Weill Cornell Center in June 2008. After completing fellowship, Dr. Mark joined the Weill Cornell Center for Lymphoma and Myeloma as a full-time clinician with a focus on clinical and translational research. He complete a Master's Program in Clinical Investigation at the Weill Cornell School of Graduate Sciences in addition to sharing clinical responsibilities at the Multiple Myeloma Center. He currently lives in Pelham, NY with his wife, two children, and two dogs.
Insurance Plans Accepted
The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.
* indicates this physician is no longer accepting new patients with this insurance plan.
- AETNA [HMO]
- AETNA [PPO]
- AETNA [Medicare]
- Aetna - Weill Cornell [POS]
- Affinity Essential
- Affinity Health Plan
- Blue Priority Network
- Emblem Select Care
- Empire Blue Cross/Blue Shield [Pathway X]
- Empire Blue Cross/Blue Shield [Pathway X Enhanced]
- Empire Blue Cross/Blue Shield [PPO]
- Empire Blue Cross/Blue Shield [EPO]
- Empire Blue Cross/Blue Shield [HMO]
- Empire Blue Cross/Blue Shield [Mediblue (Senior)]
- Fidelis Care
- GHI [CBP]
- Health First
- Health Insurance Plan of NY (HIP) [Medicare]
- Health Insurance Plan of NY (HIP) [Medicaid]
- Health Insurance Plan of NY (HIP)
- Health Plus - Amerigroup [CHP]
- Health Plus - Amerigroup
- Health Republic
- Oxford Health Plans [Liberty]
- Oxford Health Plans [Medicare Advantage]
- Oxford Health Plans [Freedom]
- Rockefeller University - CoreSource
- UHC Compass
- United Empire
- United Health Care
- United Health Care [Medicare]
- United Health Care [Community Plan]
- VNSNY CHOICE Medicare [Medicare]
- VNSNY CHOICE Medicare [HMO]
Peer Reviewed Articles:
1) Shi H, Djikeng A, Mark T, Wirtz E, Tschudi C, Ullu E. Genetic interference in Trypanosoma brucei by heritable and inducible double-stranded RNA. RNA. 6(7):1069-76, July 2000.
2) Niesvizky R, Naib T, Christos P, Jayabalan D, Furst J, Jalbrzikowski J, Zafar F, Mark T, Lent R, Pearse R, Ely S, Leonard J, Mazumdar M, Chen-Kiang S, Coleman M. Lenalidomide-induced myelosuppression is associated with renal dysfunction: Toxicity evaluation of treatment naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol. 2007 Sep;138(5):640-3.
3) Mark T, Niesvizky R. The treatment of multiple myeloma and myelodysplastic syndromes with immunomodulatory agents. US Oncol Disease. 2007.Vol 2:26-30.
4) Niesvizky R, Martínez-Baños D, Jalbrzikowski J, Christos P, Furst J, DeSancho M, Mark T, Pearse R, Mazumdar M, Zafar F, Pekle K, Rambo A. Leonard J, Jayabalan D, Coleman M. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia and Lymphoma. 2007 Dec;48(12):2330-7.
5) Niesvizky R, Jayabalan D, Christos P, Furst J, Naib T, Ely S, Jalbrzikowski J, Pearse R, Zafar F, Pekle K, Lent R, Mark T, Cho H, Shore T, Tepler J, Harpel J, Schuster M, Mathew S, Leonard J, Mazumdar M, Chen-Kiang S, Coleman M. BiRD (Biaxin®[clarithromycin]/ Revlimid®[lenalidomide]/ dexamethasone) Combination Therapy Results in High Complete and Overall Response Rates in Treatment-Naïve Symptomatic Multiple Myeloma. Blood. 2008 Feb 1;111(3):1101-9.
6) Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A, Pearse RN, Harpel J, Shore T, Schuster MW, Leonard JP, Christos PJ, Coleman M, Niesvizky R. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant. 2008 Jul;14(7):795-8.
7) Mark T, Jayabalan D, Pearse R. et al. Atypical Serum Immunofixation Patterns are frequently associated with immunomodulatory therapy and herald complete response in multiple myeloma. British Journal of Hematology. 2008. Dec;143(5):654-60.
8) Mark T, Niesvizky R, Coleman M. The Novel Agents in Multiple Myeloma: An Exciting Saga. Cancer. 2008. Nov;115(2):236-42.
9) Mark T, Martin P, Leonard JP, Niesvizky R. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2009. Jan;18(1):99-104.
10) Mark T, Coleman M, Niesvizky R. Use of Lenalidomide in Relapsed or Refractory Multiple Myeloma. Asia-Pacific Journal of Oncology & Hematology. 2009;1(2):1-5.
11) Niesvizky R, Coleman M, Mark T. Best Practices in the Management of Newly Diagnosed Multiple Myeloma Patients Who Will Not Undergo Transplant. Oncology. 2010;24(3):14-21.
12) Gay F, Rajkumar SV, Jayabalan D, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard JP, Lacy MQ, Cheng-Kiang S, Roy V, Coleman M, Lust JA, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, and Niesvizky R. Superiority Of Clarithromycin (Biaxin)-Lenalidomide-low-dose dexamethasone (BiRd) Versus Lenalidomide-low-dose Dexamethasone (Rd) As Initial Therapy for Newly Diagnosed Multiple Myeloma. Am J Hematol. 2010 Sep;85(9):664-9.
13) Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove J, Wright JJ, Chen-Kiang S and Sparano JA. Phase II trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer. 2011 Jan;117(2):336-42.
14) Cushing M, Kawaguchi K, Friedman KD, and Mark T. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease. Transfusion. 2012 Jul;52(7):1535-41
15) Elstrom RL, Martin P, Hurtado Rua S, Shore TB, Furman RR, Ruan J, Pearse RN, Coleman M, Mark T, Leonard JP, and Gergis U. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol. 2012 Apr;87(4):433-5.
16) Dimopoulos, M, Terpos E, Goldschmidt H, Alegre A, Mark T, and Niesvizky R. Treatment with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Renal Impairment. Cancer Treatment Reviews. 2012 Dec;38(8):1012-9.
17) Richardson PG, Mark T, and Lacy MQ. Pomalidomide: New immunomodulatory agent with potent antiproliferative effects. Crit Rev Oncol Hematol. 2013 Jun 17. [Epub ahead of print]
18) Rossi A, Mark T, Jayabalan D, Christos P, Zafar F, Pekle K, Pearse R, Chen-Kiang S, Coleman M, Niesvizky R. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood. 2013 Jan 8.
19) Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T. A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma. Biol Blood Marrow Transplant. 2013 Feb 20. [Epub ahead of print]
20) Niesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M, Stern J, Christos PJ, Mathews L, Shore TB, Zafar F, Pekle K, Xiang Z, Ely S, Skerret D, Chen-Kiang S, Coleman M, Lane ME. Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization. Clin Cancer Res. 2013 Mar 1. [Epub ahead of print]
21) Forsberg PA, Mark TM. Pomalidomide in the treatment of relapsed multiple myeloma. Future Oncol. 2013 Jul;9(7):939-48.
22) Gergis U, Roboz G, Shore T, Ritchie E, Mayer S, Wissa U, McKenna M, Christos P, Pearse R, Mark T, Scandura J, van Besien K, Feldman E. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biol Blood Marrow Transplant. 2013 Jul;19(7):1040-5.
23) Meadows JP, Mark TM. Management of Double-Refractory Multiple Myeloma. Curr Hematol Malig Rep. 2013 Dec;8(4):253-60.
24) Gergis U, Mayer S, Gordon B, Mark T, Pearse R, Shore T, Van Besien K. A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. Bone Marrow Transplant. 2014 Feb 17. doi: 10.1038/bmt.2014.11. [Epub ahead of print]
25) Mark TM, Bowman IA, Rossi AC, Shah M, Rodriguez M, Quinn R, Pearse RN, Zafar F, Pekle K, Jayabalan D, Ely S, Coleman M, Chen-Kiang S, Niesvizky R. T-BiRD (thalidomide, clarithromycin, lenalidomide and dexamethasone) therapy in newly diagnosed, symptomatic multiple myeloma. Leuk Lymphoma. 2014 Feb 28.
26) Mark TM, Coleman M, Niesvizky R. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. Leuk Res. 2014 Mar 13.
27) Khagi Y, Mark TM. Potential Role of Daratumumab in the Treatment of Multiple Myeloma. Onco Targets Ther. 2014 Jun 18;7:1095-100.
Mark T, Pearse RN. Pathophysiology of Bone Disease in Multiple Myeloma. Myeloma Therapy: Pursuing the Plasma Cell. Edited by: S. Lonial. Humana Press, Totowa, NJ. December 2008. pp 435-454.
Chin O, Mark T. Love, Olivia. WestBow Press. February 2012.
Ely S, Niesvizky R, Mark T. B-cell immunoproliferative disorders, including multiple myeloma and primary amyloidosis. Knowles’ Neoplastic Hematopathology, 3rd edition. Lippincott Williams & Wilkins. December 2013.
Honors and Awards
1994 – National Merit Scholar
2007 – 1st Place: Department of Medicine Fellows Award
2007 – Hermione Foundation Sponsored Fellowship Grant
2008 - Endowed Assistant Professorship - Morton Coleman Assistant Professor in Multiple Myeloma
2008 – American Society of Hematology Clinical Research Training Institute Award
2012-2014 – Multiple Myeloma Research Foundation Laugh for Life, 10th Anniversary, Honorary Committee Member
2014 – Member of the International Multiple Myeloma Working Group
- Medical Oncology
- Castleman's Disease
- Monoclonal Gammopathy of Undetermined Significance
- Plasma Cell Leukemia
- Multiple Myeloma
- Plasma Cell Dyscrasia
- POEMS Syndrome
- Smoldering Myeloma
- Waldenstrom's Disease
- Waldenstrom's Macroglobulinemia
- Internal Medicine
- Medical Oncology
- M.D., State University of New York at Stony Brook, School of Medicine, 2002
- M.Sc., Weill Graduate School of Medical Sciences of Cornell University, 2010